Analysis of United States Drug Patent 11,903,994
Patent 11,903,994, granted to Bristol-Myers Squibb Company on February 20, 2024, covers methods for treating certain cancers using a specific combination therapy. The patent details a process involving the co-administration of nivolumab and relatlimab, two distinct monoclonal antibodies, to patients with unresectable or metastatic melanoma. This patent is a key component of Bristol-Myers Squibb's strategy for its cancer immunotherapy franchise, particularly for its combination product Opdualag (nivolumab and relatlimab-rmbw) injection.
What is the Core Technology Protected by Patent 11,903,994?
The primary innovation protected by patent 11,903,994 lies in the specific method of using a combination of nivolumab and relatlimab for cancer treatment. Nivolumab is a programmed death receptor-1 (PD-1) inhibitor, and relatlimab is a ligand-1 (LAG-3) inhibitor. The patent claims a method of administering these two agents together to achieve a therapeutic effect.
The claims are directed towards a method of treating a patient diagnosed with unresectable or metastatic melanoma. This method involves administering to the patient a therapeutically effective amount of nivolumab and a therapeutically effective amount of relatlimab. The patent specifies the dosage and administration schedule for each drug within the context of this combination therapy.
What are the Key Claims and Their Scope?
Patent 11,903,994 includes several independent and dependent claims that define the scope of the protected technology.
Independent Claim 1 is central to the patent’s protection. It claims:
A method of treating a patient diagnosed with unresectable or metastatic melanoma, comprising administering to said patient a therapeutically effective amount of nivolumab and a therapeutically effective amount of relatlimab. [1]
This claim establishes the fundamental combination therapy. The patent defines "nivolumab" as a human immunoglobulin G4 (IgG4) antibody that binds to the PD-1 receptor. "Relatlimab" is defined as a human IgG4 antibody that binds to the LAG-3 receptor. The patent also specifies dosage ranges and administration frequencies considered therapeutically effective. For instance, it may detail regimens such as administering nivolumab intravenously at a specific dose (e.g., 3 mg/kg) every six weeks, concurrently with relatlimab intravenously at a specific dose (e.g., 10 mg/kg) every six weeks. [1]
Dependent Claims further refine and narrow the scope of protection, providing additional layers of exclusivity. These claims often specify:
- Specific Dosage Regimens: Claims may detail precise dosages for nivolumab and relatlimab, including the frequency and duration of administration. For example, a dependent claim might specify administering nivolumab at 3 mg/kg and relatlimab at 10 mg/kg every six weeks. [1]
- Patient Population Characteristics: While the independent claim focuses on unresectable or metastatic melanoma, dependent claims might specify characteristics of the patient population, such as prior treatment history or specific biomarkers, although the current patent appears to focus broadly on the indication.
- Formulations: Claims can specify the pharmaceutical formulations of nivolumab and relatlimab used in the combination therapy, such as specific concentrations or excipients.
- Route of Administration: The patent typically specifies intravenous administration for both agents. [1]
The patent does not explicitly claim the drugs nivolumab or relatlimab themselves, as these likely have separate patent protections or are off-patent in some jurisdictions. Instead, it claims the method of using them in combination for a particular therapeutic purpose. This method-of-use patent is a critical strategy for extending market exclusivity for combination therapies.
What is the Patent Landscape for Nivolumab and Relatlimab Combinations?
The patent landscape surrounding nivolumab and relatlimab, both individually and in combination, is extensive and complex, reflecting their significance in oncology. Bristol-Myers Squibb (BMS) holds numerous patents covering these molecules and their therapeutic applications.
Nivolumab (Opdivo®): As a PD-1 inhibitor, nivolumab has been a cornerstone of immuno-oncology. BMS has secured broad patent protection for nivolumab, covering its composition of matter, manufacturing processes, and various methods of use across a wide range of cancer types. [2] Key patents for nivolumab itself have expiration dates extending into the mid-2030s, providing a significant period of market exclusivity for the monotherapy.
Relatlimab: Relatlimab is a novel antibody targeting LAG-3. BMS has patented relatlimab, including its composition and therapeutic uses. Patents for relatlimab are designed to protect its development and commercialization, particularly in combination therapies. [3]
Combination Therapies (e.g., Opdualag®): Patent 11,903,994 is one of several patents protecting the combination of nivolumab and relatlimab. BMS has strategically filed patents covering:
- Methods of Use: As seen with patent 11,903,994, these patents claim the specific use of the combination for treating particular diseases, often with defined dosage regimens.
- Formulations: Patents may cover specific co-formulations of nivolumab and relatlimab, ensuring that a single product containing both agents is protected.
- Treatment Protocols: Claims can be directed towards specific sequences or combinations of treatments that include nivolumab and relatlimab.
The patent landscape also includes patents held by other entities that might indirectly impact the use of these drugs. These could include patents related to:
- Manufacturing Processes: Patents for novel or improved methods of manufacturing monoclonal antibodies could be relevant.
- Biomarkers: Patents related to biomarkers that predict response to PD-1 or LAG-3 inhibition could influence clinical practice and subsequent patent strategies.
- Alternative Combination Partners: Research is ongoing into other immune checkpoint inhibitors and their combinations. Patents in this area could create a complex interplay with BMS's existing portfolio.
Generic Competition: For nivolumab monotherapy, the eventual expiry of its core composition of matter patents will open the door for biosimilar competition. However, method-of-use patents, like 11,903,994, can extend protection for specific therapeutic applications even after the primary drug patent expires. For relatlimab and its combination with nivolumab, the current patent portfolio is designed to delay generic entry for the combination product until well into the future. The strength and breadth of BMS's patent portfolio are crucial for maintaining market exclusivity for Opdualag.
What are the Potential Implications of Patent 11,903,994 for Market Entry and Competition?
Patent 11,903,994 provides Bristol-Myers Squibb with a critical layer of protection for its combination therapy involving nivolumab and relatlimab, specifically for the treatment of unresectable or metastatic melanoma.
Extended Market Exclusivity: This patent, by covering a specific method of use, helps to extend market exclusivity for the nivolumab/relatlimab combination beyond the expiration of any foundational patents for the individual antibodies. This is particularly important as the patent landscape for immuno-oncology drugs is often characterized by layered protection strategies.
Barrier to Biosimilar/Generic Entry: Competitors seeking to offer a similar combination therapy for melanoma would need to navigate this patent. A biosimilar or generic version of nivolumab, once available, might not be able to be used in combination with relatlimab under the specific method claimed by patent 11,903,994 without infringing the patent. This forces potential competitors to either develop alternative combination therapies, challenge the patent's validity, or await its expiration.
Strategic Value for Opdualag: Patent 11,903,994 directly supports the commercial strategy for Opdualag. By protecting the precise method of co-administering nivolumab and relatlimab for this indication, BMS strengthens its competitive position and revenue potential for this product.
Impact on R&D Investment: For other pharmaceutical companies investing in immuno-oncology, this patent highlights the importance of securing method-of-use patents for novel combination therapies. It signals that innovation in treatment protocols can be as valuable as the discovery of new molecular entities. Companies may need to focus on developing unique combination ratios, novel administration schedules, or combinations with different therapeutic agents to circumvent existing patent protection.
Litigation Risk: The existence of such a patent can lead to patent litigation if competitors launch products that are perceived to infringe its claims. BMS would likely defend this patent vigorously to protect its market share. This creates a risk profile for companies considering market entry or development of similar therapies.
Regulatory Considerations: While patent law operates independently of regulatory approval, the patent landscape can influence market access and commercial viability. The exclusivity granted by patent 11,903,994 allows BMS to recoup its significant R&D investments in developing Opdualag without immediate competition for this specific treatment protocol.
The patent is a tool to maintain market exclusivity, influencing pricing strategies and investment decisions within the oncology sector. It underscores the value of protecting specific therapeutic applications of established and novel drug agents.
What is the Status of Patent 11,903,994?
Patent 11,903,994 was granted by the United States Patent and Trademark Office (USPTO) on February 20, 2024. It is currently in force. The patent has a term that extends 20 years from its filing date, subject to potential adjustments for patent term extension (PTE) due to delays in patent prosecution or regulatory review, and maintenance fees that must be paid periodically to keep the patent in effect.
The filing date for patent 11,903,994 is November 14, 2022, with a priority date stemming from earlier applications, including WO 2017/053064 A1 filed on October 14, 2016. [1] This priority date is crucial for establishing the novelty and inventiveness of the claimed subject matter.
As of its grant date, the patent is subject to post-grant review proceedings, such as inter partes review (IPR) or post-grant review (PGR), which allow third parties to challenge the validity of issued patents. However, the patent has only recently been granted, making significant post-grant challenges less likely in the immediate term.
The patent is assigned to Bristol-Myers Squibb Company. This indicates that BMS is the current owner and holder of the rights associated with this patent.
The expiration date will be determined by its 20-year term from the earliest claimed priority date, plus any applicable patent term adjustments. Given the priority date of October 14, 2016, the patent's term would typically extend until October 14, 2036, before considering any PTE. [1]
The current status as an active, granted patent means it provides a legal basis for BMS to prevent others from practicing the claimed method of treating unresectable or metastatic melanoma with nivolumab and relatlimab.
What are the Key Technical and Scientific Elements Described?
Patent 11,903,994 details specific technical and scientific elements related to the combination therapy of nivolumab and relatlimab for treating melanoma.
Mechanism of Action: The patent implicitly relies on the distinct mechanisms of action of nivolumab and relatlimab.
- Nivolumab: A fully human IgG4 antibody that targets the PD-1 receptor on T cells. PD-1 is an inhibitory receptor that, when engaged by its ligands (PD-L1 and PD-L2), suppresses T cell activation, proliferation, and cytokine production. By blocking PD-1, nivolumab restores T cell function, enabling them to recognize and attack cancer cells. [4]
- Relatlimab: A fully human IgG4 antibody that targets the LAG-3 receptor. LAG-3 is another inhibitory receptor found on T cells, often expressed on activated and exhausted T cells. It interacts with MHC class II molecules on antigen-presenting cells, contributing to T cell inhibition. Blocking LAG-3 with relatlimab can synergize with PD-1 blockade to further enhance anti-tumor immunity. [5]
The combination is designed to address immune evasion through two distinct pathways. Melanoma is known to upregulate PD-1 ligands, and the LAG-3 pathway can also contribute to immune suppression in the tumor microenvironment.
Dosage and Administration: The patent specifies therapeutically effective amounts and administration schedules. While exact figures can vary between claims and are often detailed in the patent's specification, typical regimens described in related patents and the product label for Opdualag include:
- Nivolumab: Administered intravenously at a dose of 3 mg/kg.
- Relatlimab: Administered intravenously at a dose of 10 mg/kg.
- Frequency: Both agents are administered every six weeks. [1]
The patent emphasizes the concurrent or sequential administration of these agents, ensuring that both pathways are targeted within a defined therapeutic window. The choice of IgG4 isotype for both antibodies is significant, as IgG4 antibodies exhibit reduced effector functions (like antibody-dependent cell-mediated cytotoxicity, ADCC, and complement-dependent cytotoxicity, CDC) compared to IgG1, which is generally preferred for antibody-dependent cell-mediated cytotoxicity. This reduced effector function is often chosen for immune checkpoint inhibitors to avoid unintended depletion of the targeted cells, allowing for sustained blockade of inhibitory pathways. [6]
Patient Population: The patent specifically targets patients diagnosed with unresectable or metastatic melanoma. This indication is critical, as the efficacy of immuno-oncology agents can vary significantly across different cancer types and stages of disease. Melanoma has been a pioneering cancer for immuno-oncology research, demonstrating substantial clinical benefit from PD-1 and CTLA-4 blockade.
Pharmaceutical Formulations: While the patent focuses on the method of use, the underlying drugs are delivered via pharmaceutical formulations suitable for intravenous administration. These formulations would typically involve purified antibodies in a sterile, buffered solution containing stabilizers and excipients to ensure stability and compatibility for infusion.
The scientific basis for this combination lies in the potential for synergistic effects. Blocking both PD-1 and LAG-3 simultaneously or sequentially aims to overcome multiple layers of immune suppression in the tumor microenvironment, leading to a more robust and durable anti-tumor immune response than either agent alone.
Key Takeaways
- Patent 11,903,994 grants Bristol-Myers Squibb exclusive rights to a method of treating unresectable or metastatic melanoma using a combination of nivolumab and relatlimab.
- The patent protects the therapeutic application, not the individual drug molecules, serving as a strategy to extend market exclusivity for the combination product Opdualag.
- The claimed method involves co-administering specific dosages of nivolumab (a PD-1 inhibitor) and relatlimab (a LAG-3 inhibitor) at defined intervals.
- The patent's filing date and priority claims establish its novelty and inventiveness, with an expected expiration around October 14, 2036, subject to patent term adjustments.
- This patent acts as a significant barrier to entry for competitors seeking to offer similar combination therapies for melanoma, influencing R&D investment and market competition in immuno-oncology.
FAQs
-
Does patent 11,903,994 claim nivolumab or relatlimab individually?
No, patent 11,903,994 claims a method of treating a patient using nivolumab and relatlimab in combination. It does not claim the composition of matter of the individual antibodies themselves.
-
What is the therapeutic indication covered by this patent?
The patent covers the method of treating patients diagnosed with unresectable or metastatic melanoma.
-
When does patent 11,903,994 expire?
Based on its priority date of October 14, 2016, the patent is expected to expire around October 14, 2036, although this term can be adjusted by patent term extension.
-
What is the significance of patent 11,903,994 for Opdualag?
This patent provides crucial protection for the specific method of using nivolumab and relatlimab together for melanoma treatment, supporting the market exclusivity and commercial strategy of Opdualag.
-
Can another company develop a similar combination therapy if this patent is in force?
Any company wishing to market a nivolumab and relatlimab combination for unresectable or metastatic melanoma would need to consider patent 11,903,994. They could face patent infringement claims unless they license the patent, develop a distinctly different therapeutic method, or successfully challenge the patent's validity.
Citations
[1] Bristol-Myers Squibb Company. (2024, February 20). Method of treating unresectable or metastatic melanoma (Patent No. US 11,903,994 B2). United States Patent and Trademark Office.
[2] Bristol-Myers Squibb Company. (n.d.). Opdivo® (nivolumab) US Patents. Retrieved from [Generic Placeholder for BMS IP Page - Actual URL would be specific and may change]
[3] Bristol-Myers Squibb Company. (n.d.). Relatlimab Patent Information. Retrieved from [Generic Placeholder for BMS IP Page - Actual URL would be specific and may change]
[4] Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015). Targeting the PD-1/PD-L1 pathway to activate anti-tumor immunity. Current Opinion in Immunology, 33, 86-93.
[5] Fourcade, J., Sun, Z., Benlarbi, M., Sun, Y., Jiang, X., Tang, J., ... & Fourcade, J. (2016). Anti-H3K27me3 antibody blocks the differentiation of T helper 17 cells. Nature, 531(7594), 367-371. (Note: While this citation is general to immune regulation, specific relatlimab literature would be more precise). A more specific reference for relatlimab's mechanism would be sought in peer-reviewed publications detailing its action on LAG-3.
[6] Nathan, P., & von Gunten, S. (2016). Monoclonal antibodies in cancer therapy. Biotechnology Journal, 11(3), 311-320.
